Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2016/03/25 17:22:36」(JST)

wiki en

Pentostatin (or deoxycoformycin, trade name Nipent, manufactured by SuperGen) is an anticancer chemotherapeutic drug.^[1]

Mechanism

It is classified as a purine analog, which is a type of antimetabolite.

It mimics the nucleoside adenosine and thus inhibits the enzyme adenosine deaminase, interfering with the cell's ability to process DNA.^[2]

Cancer cells generally divide more often than healthy cells; DNA is highly involved in cell division (mitosis) and drugs which target DNA-related processes are therefore more toxic to cancer cells than healthy cells.

Uses

Pentostatin is used to treat hairy cell leukemia.^[3] It is given by intravenous infusion once every two weeks for three to six months.

Additionally, pentostatin has been used to treat steroid-refractory acute and chronic graft-versus-host disease.^[4]

Pentostatin is also used in chronic lymphocytic leukemia (CLL) patients who have relapsed.

References

^ Kay NE, Geyer SM, Call TG, et al. (January 2007). "Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia". Blood 109 (2): 405–11. doi:10.1182/blood-2006-07-033274. PMC 1785105. PMID 17008537.
^ Sauter C, Lamanna N, Weiss MA (September 2008). "Pentostatin in chronic lymphocytic leukemia". Expert Opin Drug Metab Toxicol 4 (9): 1217–22. doi:10.1517/17425255.4.9.1217. PMID 18721115.
^ Cannon T, Mobarek D, Wegge J, Tabbara IA (October 2008). "Hairy cell leukemia: current concepts". Cancer Invest. 26 (8): 860–5. doi:10.1080/07357900801965034. PMID 18798068.
^ Bolaños-Meade J, Jacobsohn DA, Margolis J, Ogden A, Wientjes MG, Byrd JC, Lucas DM, Anders V, Phelps M, Grever MR, Vogelsang GB (April 2005). "Pentostatin in steroid-refractory acute graft-versus-host disease". J Clin Onc 23 (12): 2661–8. doi:10.1200/JCO.2005.06.130. PMID 15837980.

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. T細胞性前リンパ性白血病の治療 treatment of t cell prolymphocytic leukemia
2. 有毛細胞白血病の治療 treatment of hairy cell leukemia
3. 症候性または進行した慢性リンパ性白血病に対する初期治療の選択 selection of initial therapy for symptomatic or advanced chronic lymphocytic leukemia
4. 急性移植片対宿主病の治療 treatment of acute graft versus host disease
5. プリンアナログ療法後の自己免疫性合併症 autoimmune complications following purine analog therapy

English Journal

High-Dose Sirolimus and Immune-Selective Pentostatin plus Cyclophosphamide Conditioning Yields Stable Mixed Chimerism and Insufficient Graft-versus-Tumor Responses.

Mossoba ME1, Halverson DC1, Kurlander R2, Schuver BB1, Carpenter A1, Hansen B1, Steinberg SM3, Ali SA1, Tageja N1, Hakim FT1, Gea-Banacloche J1, Sportes C4, Hardy NM5, Hickstein DD1, Pavletic SZ1, Khuu H6, Sabatini M6, Stroncek D6, Levine BL7, June CH7, Mariotti J8, Rixe O9, Fojo AT10, Bishop MR11, Gress RE1, Fowler DH12.
Clinical cancer research : an official journal of the American Association for Cancer Research.Clin Cancer Res.2015 Oct 1;21(19):4312-20. doi: 10.1158/1078-0432.CCR-15-0340. Epub 2015 Jun 12.
PURPOSE: We hypothesized that lymphoid-selective host conditioning and subsequent adoptive transfer of sirolimus-resistant allogeneic T cells (T-Rapa), when combined with high-dose sirolimus drug therapy in vivo, would safely achieve antitumor effects while avoiding GVHD.EXPERIMENTAL DESIGN: Patient
PMID 26071480

An unusual indication for splenectomy in hairy cell leukaemia: a report of three cases with persistent splenomegaly after chemoimmunotherapy.

Sarid N1, Ahmad HN2, Wotherspoon A3, Dearden CE3, Else M4, Catovsky D4.
British journal of haematology.Br J Haematol.2015 Sep 25. doi: 10.1111/bjh.13767. [Epub ahead of print]
We describe three cases of relapsed hairy cell leukaemia (HCL) treated with pentostatin plus rituximab. All three achieved bone marrow complete remission but had persistent splenomegaly and hypersplenism. Because of the clinical uncertainty of its significance, they were all splenectomized. The sple
PMID 26403440

Potential breakthroughs with investigational drugs for hairy cell leukemia.

Robak T1, Wolska A, Robak P.
Expert opinion on investigational drugs.Expert Opin Investig Drugs.2015 Sep 2:1-13. [Epub ahead of print]
INTRODUCTION: Hairy cell leukemia (HCL) is a rare subtype of B-cell chronic lymphoid leukemia. It is characterized by progressive pancytopenia, splenomegaly and infiltrations of the bone marrow, liver and spleen. Over the last few years, several new immunological drugs, particularly immunotoxins, BR
PMID 26329588

Related Pictures

Nipent - FDA prescribing information, side effects and uses Nipent - Pentostatin lijkt effectief bij verschillende vormen van bloedkanker pentostatin intravenous : Uses, Side Effects, Interactions, Pictures, Warnings Nipent intravenous : Uses, Side Effects, Interactions, Pictures, Warnings & Dosing - WebMD Nipent (Hospira, Inc.): FDA Package Insert Nipent™ (Pentostatin for Injection) | Pfizerinjectables Nipent for Injection (SuperGen), Drug Reference Encyclopedia Nipent 10 mg 1 Flakon ilacı fiyatı, yan etkileri, endikasyonları nedir

★リンクテーブル★

リンク元

「ペントスタチン」

Pentostatin
Systematic (IUPAC) name
	(R)-3-((2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol
Clinical data
Trade names	Nipent
AHFS/Drugs.com	monograph
MedlinePlus	a692004
Pregnancy; category	US: D (Evidence of risk); ;
Routes of; administration	Intravenous
Legal status
Legal status	CA: ℞-only; UK: POM (Prescription only); US: ℞-only;
Pharmacokinetic data
Bioavailability	n/a
Protein binding	4%
Metabolism	Hepatic, minor
Biological half-life	2.6 to 16 hours, mean 5.7 hours
Identifiers
CAS Number	53910-25-1
ATC code	L01XX08 (WHO)
PubChem	CID 439693
IUPHAR/BPS	4805
DrugBank	DB00552
ChemSpider	388759
UNII	395575MZO7
KEGG	D00155
ChEMBL	CHEMBL1580
Chemical data
Formula	C11H16N4O4
Molar mass	268.269 g/mol
	SMILES n1c3c(n(c1)[C@@H]2O[C@@H]([C@@H](O)C2)CO)N\C=N/C[C@H]3O ;
	InChI InChI=1S/C11H16N4O4/c16-3-8-6(17)1-9(19-8)15-5-14-10-7(18)2-12-4-13-11(10)15/h4-9,16-18H,1-3H2,(H,12,13)/t6-,7+,8+,9+/m0/s1 ; Key:FPVKHBSQESCIEP-JQCXWYLXSA-N ;
(verify)

　　[★]

英: pentostatin
商: コホリン, Nipent
関: Aspergillus nidulans

[pmid17008537-1] Kay NE, Geyer SM, Call TG, et al. (January 2007). "Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia". Blood 109 (2): 405–11. doi:10.1182/blood-2006-07-033274. PMC 1785105. PMID 17008537.

[pmid18721115-2] Sauter C, Lamanna N, Weiss MA (September 2008). "Pentostatin in chronic lymphocytic leukemia". Expert Opin Drug Metab Toxicol 4 (9): 1217–22. doi:10.1517/17425255.4.9.1217. PMID 18721115.

[pmid18798068-3] Cannon T, Mobarek D, Wegge J, Tabbara IA (October 2008). "Hairy cell leukemia: current concepts". Cancer Invest. 26 (8): 860–5. doi:10.1080/07357900801965034. PMID 18798068.

[PMID15837980-4] Bolaños-Meade J, Jacobsohn DA, Margolis J, Ogden A, Wientjes MG, Byrd JC, Lucas DM, Anders V, Phelps M, Grever MR, Vogelsang GB (April 2005). "Pentostatin in steroid-refractory acute graft-versus-host disease". J Clin Onc 23 (12): 2661–8. doi:10.1200/JCO.2005.06.130. PMID 15837980.

匿名

検索

案内

案内

Nipent